Parkinson's disease and sleep

Sleep Medicine Reviews

Volumn 7, Issue 2, 2003, Pages 115-129

  Garcia Borreguero, Diego ^a   Larrosa, Oscar ^a   Bravo, Mauricio ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Disorders of initiation and maintenance of sleep; Dopaminergic drugs; Excessive daytime sleepiness; Parkinson's disease; REM sleep behavior disorder

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; SELEGILINE;

ACCIDENT; BREATHING; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; HUMAN; HYGIENE; MENTAL DISEASE; NERVE DEGENERATION; NONHUMAN; PARASOMNIA; PARKINSON DISEASE; PATHOGENESIS; REM SLEEP; REVIEW; SLEEP DISORDER; SOMNOLENCE;

EID: 0037375896     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1053/smrv.2002.0229     Document Type: Article

References (117)

1. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL. Sleep disruption in the course of chronic levoclopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 1982; 5(2): 183-94.
2. van Hilten JJ, Weggeman M, van der Welde EA, Kerkhof GA, van Dijk JG, Roos RAC. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm [P-D Sect] 1993; 5: 235-244.
3. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998; 13(6): 895-899.
4. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Movement disorders 1990; 5: 280-285.
5. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11(6): 512-519.
6. Wetter TH, Collado-Seidel V, Pollmächer T, Yassouridis A, Trenkwalder C. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 2000; 23(3): 361-367.
7. Miele V, Proli F, Salzarulo P. Electropolygraphic aspects of sleep in patients with parkinsonism. Riv Sper Freniatr Med Leg Alien Ment 1970; 94(1): 69-82.
8. Kales A, Ansel RD, Markham CH, Scharf MB, Tan TL. Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration. Clin Pharmacol Ther 1971; 12(2): 397-406.
9. Kendel K, Beck U, Wita C, Hohneck E, Zimmermann H. Influence of L-DOPA on night sleep in parkinsonian patients. Arch Psychiatr Nervenkr 1972; 216(1): 82-100.
10. Mouret J. Differences in sleep in patients with Parkinson's disease. Electroencephalogr Clin Neurophysiol 1975; 38(6): 637-673.
11. Traczynska-Kubin D, Atzef E, Petre-Quadens O. Sleep in parkinsonism. Acta Neurol Psychiatr Belg 1969; 69(9): 727-733.
12. Poewe W, Högl B. Parkinson's disease and sleep. Current Opinion in Neurology 2000; 13(423): 426.
13. Ferrini-Strambi L, Franceschi M, Pinto P, Zucconi M, Smirne S. Respiration and heart rate variability during sleep in untreated Parkinson patients. Gerontology 1992; 38(1-2): 92-98.
14. Hogl BE, Gomez-Arevalo G, Garcia S, Scipioni O, Rubio M, Blanco M, Gershanik OS. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology 1998; 50(5): 1332-1339.
15. Askenasy JJM, Mendelsohn L, Katz A, et al. Basal ganglia disorders with marked circadian fluctuations. [Abstract] Sleep Research 1985; 14: (142).
16. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of L-DOPA. J Neural Transm Park Dis Dement Sect 1993; 5(3): 227-234.
17. Askenasy JJ. Sleep in Parkinson's disease. Acta Neurol Scand 1993; 87(3): 167-170.
18. Stern M, Roffwarg H, Duvoisin R. The parkinsonian tremor in sleep. J Nerv Ment Dis 1968; 147(2): 202-210.
19. Fish DR, Sawyers D, Allen PJ, Blackie JD, Lees AJ, Marsden CD. The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. Arch Neural 1991; 48(2): 210-214.
20. Askenasy JJ, Yahr MD. Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep. J Neural Neurosurg Psychiatry 1990; 53(9): 749-753.
21. Trenkwalder C. Sleep dysfunction in Parkinson's disease. Clin Neurosci 1998; 5(2): 107-114.
22. Chaudhuri KR, Appiah-Kubi LS, Trenkwalder C. Restless legs syndrome. J Neural Neurosurg Psychiatry 2001; 71(2): 143-146.
23. Aldrich MS, Kryger M, Roth T, Dement W (eds). Principles and practice of sleep medicine. 3rd ed. Philadelphia: Saunders; 2000; Parkinsonism. pp. 1051-1057.
24. Askenasy JJ, Yahr MD. Different laws govern motor activity in sleep than in wakefulness. J Neural Transm Gen Sect 1990; 79(1-2): 103-111.
25. van Hilten B, Hoff JI, Middelkoop HA, van der Velde EA, Kerkhof GA, Wauquier A, Kamphuisen HA, Roos RA. Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring. Arch Neural 1994; 51(9): 922-928.
26. Bertolucci PH, Andrade LA, Lima JG, Carlini EA. Total sleep deprivation and Parkinson disease. Arq Neuropsiquiatr 1987; 45(3): 224-230.
27. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, Agid Y. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55(2): 281-288.
28. Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978; 43(2): 143-151.
29. Klawans HL, Moskovitz C, Nausieda PA, Weiner WJ. Levodopa-induced dopaminergic hypersensitivity in the pathogenesis of psychiatric and neurologic disorders. Int J Neural 1979; 13(1-4): 225-236.
30. Schenck CH, Hurwitz TD, Mahowald MW. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res 1993; 2(4): 224-231.
31. Schenck CH, Mahowald MW. REM sleep parasomnias. Neural Clin 1996; 14(4): 697-720.
32. Schenck CH, Bundlie SR, Patterson AL, Mahowald MW. Rapid eye movement sleep behavior disorder. A treatable parasomnia affecting older adults. JAMA 1987; 257(13): 1786-1789.
33. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neural 1993; 34(5): 710-714.
34. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998; 51(2): 526-529.
35. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46(2): 388-393.
36. Schenck CH, Milner DM, Hurwitz TD, Bundlie SR, Mahowald MW. A polysomnographic and clinical report on sleep-related injury in 100 adult patients. Am J Psychiatry 1989; 146(9): 1166-1173.
37. American Sleep Disorders Association. Diagnostic Classification Steering Committee. ASDA, ed. The International Classification of Sleep Disorders. Diagnostic and Coding Manual. Rochester, MN: 1990.
38. Garcia-Borreguero D, Caminero AB, Larrosa O, et al. Decreased phasic activity during REM sleep in untreated Parkinson's disease. [Abstract] Sleep 2000; 23: (Abstract Supplement 2) A330.
39. Montplaisir J, Petit D, Filipini D et al. REM sleep characteristics in patients with Parkinson's disease associated or not with REM sleep behavior disorder. [Abstract] Sleep 2000; 23 (Suppl. 2): A103.
40. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50(6): 743-755.
41. Jellinger KA. Post mortem studies in Parkinson's disease - it possible to detect brain areas for specific symptoms? J Neural Transm 1999; 56 (Suppl.): 1-29.
42. Askenasy JJ. Sleep in Parkinson's disease. Acta Neurol Scand 1993; 87(3): 167-170.
43. Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep 1997; 29(9): 757-788.
44. Lai YY, Siegel JM. Pontomedullary glutamate receptors mediating locomotion and muscle tone suppression. J Neurosci 1991; 11(9): 2931-2937.
45. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000; 123(6): 1155-1160.
46. Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Movement disorders 1996; 11 (2): 214-216.
47. Hardie RJ, Efthimiou J, Stern GM. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatry 1986; 50: 1326.
48. Greulich W, Schäfer D, Georg WM, Schläfke ME. Sleep behaviour in patients with PD. Somnology 1998; 2: 163-171.
49. Hovestadt A, Bogaard JM, Meerwaldt JD, van der Meche FGA, Stigt J. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989; 52: 329-333.
50. Corbin DO, Williams AC. Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry 1987; 50: 821-822.
51. Vincken WG, Gauthier SG, Dollfus RE, Hanson R, Darauay CM, Cosio MG. Involvement of upper-airway muscles in extrapiramidal disorders. A cause of airflow limitation. N Engl J Med 1984; 311: 438-442.
52. Fitzpatrick AJ. Upper airway obstruction in Parkinson's disease. Anaesth Intensive Care 1995; 23: 367-369.
53. Vincken WG, Darauay CM, Cosio MG. Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease. Chest 1989; 96: 210-212.
54. Brescia Morra V, Polverino M, De Luca G, Luca G, Landi P, Galdi A, Campanella G. Upper airway muscles dysfunction and levodopa responsiveness in Parkinson's disease. Acta Neurol (Napoli) 1992; 14: 512-518.
55. de Bruin PF, de Bruin VM, Lees AJ, Pride NB. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease. Am Rev Respir Dis 1993; 148(6 Pt1): 1576-1580.
56. Zupnick HM, Brown LK, Miller A, Moros DA. Respiratory dysfunction due to L-DOPA therapy for Parkinsonism: Diagnosis using serial pulmonary function tests and respiratory inductive pletysmograph. Am J Med 1990; 86: 109-114.
57. De Keyser J and Vincken W. L-Dopa-induced respiratory disturbance in Parkinson's disease suppressed by tiapride. Neurology 1985; 35(2): 235-237.
58. Riley DE, Grossman G, Martin L. Acute respiratory faillure from dopamine agonist withdrawal. Neurology 1992; 42: 1843-1844.
59. Onodera H, Okabe S, Kikuchi Y, Tsuda T, Itoyama Y. Impaired chemosensivity and perception of dyspnoea in Parkinson's disease. Lancet 2000; 356: 739-740.
60. Röggla G, Weber W, Röggla M. Parkinson's disease and impaired chemosensitivity to hypoxia. [Abstract] Lancet 2000; 356: 2099.
61. 2 responsiveness in Parkinson's disease: Evidence for a role of CNS dopamine in ventilatory control. [Abstract] Am Rev Respir Dis 1985; 131: A297.
62. Pal PK, Calne S, Samii A, Fleming JAE. A review of normal sleep and its disturbances in Parkinson's disease. Parkinsonism and Related Disorders 1999; 5: 1-17.
63. Goetz CG, Wilson RS, Tanner CM et al. Yahr MD, Bergman KJ. Advances in Neurology: Parkinson's disease. New York: Raven Press; 1986; Relationship among pain, depression, and sleep alterations in Parkinson's disease, p. 345.
64. Goetz CG, Wilson RS, Tanner CM et al. Yahr MD, Bergman KJ. Advances in Neurology: Parkinson's disease. New York: Raven Press; 1986; Relationship among pain, depression, and sleep alterations in Parkinson's disease, p. 345.
65. Kostic VS, Susic V, Przedborski S, Sternic N. Sleep EEG in depressed and nondepressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1991; 3: 176-179.
66. Menza MA, Rosen RC. Sleep in Parkinson's disease. Psychosomatics 1995; 36(3): 262-266.
67. Whitney CW, Enright PL, Newman AB, Bonekat W, Foley D, Quan SF. Correlates of daytime sleepiness in 4578 elderly persons: the cardiovascular health study. Sleep 1998; 21: 27-36.
68. Henderson R, Kurlan R, Kersum JM, Como P. Preliminary examination of the co-morbidity of anxiety and depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 4: 257-264.
69. Ondo WG, Dat Vuong K, Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57(8): 1392-1396.
70. Carskadon MA. ed. Sleep and alertness. New York: Raven Press, 1989. p. 53.
71. Rye DB, Bliwise DL, Dihenia B, Gurecki P. FAST TRACK: daytime sleepiness in Parkinson's disease. J Sleep Res 2000; 9(1): 63-69.
72. Rye DB, Johnston LH, Watts RL, Bliwise DL. Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset. Neurology 1999; 53(8): 1868-1870.
73. Chaudhuri KR, Ellis C, Love-Jones S, Thomaides T, Clift S, Mathias CJ, Parkes JD. Postprandial hypotension and parkinsonian state in Parkinson's disease. Mov Disord 1997; 12(6): 877-884.
74. Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998; 1(1): 49-61.
75. Galarraga E, Corsi-Cabrera M, Sangri M. Reduction in paradoxical sleep after L-dopa administration in rats. [Abstract] Behav Neural Biol 1986; 46 (3): 249-256.
76. Boivin DB, Montplaisir J. The effects of L-DOPA on excessive daytime sleepiness in narcolepsy. Neurology 1991; 41: 1267-1269.
77. Gillin JC, Post RM, Wyatt RJ, Snyder F, Bunney WE Jr. REM inhibitory effect of L-DOPA infusion during human sleep. Electroencephalogr Clin Neurophysiol 1973; 35(2): 181-186.
78. Nakazawa Y, Tachibana H, Kotorii M, Ogata M. Effects of L-DOPA on natural night sleep and on rebound of REM sleep. Folia Psychiatr Neurol Jpn 2001; 27(3): 223-230.
79. Boivin DB, Montplaisir J, Poirier G. The effects of L-DOPA on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol 1989; 12(4): 339-345.
80. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Saf 2001; 24(11): 863-868.
81. Montastruc JL, Brefel-Courbon C, Senard JM, Bagheri H, Ferreira J, Rascol O, Lapeyre-Mestre M. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001; 24(3): 181-183.
82. Trampus M, Ferri N, Monopoli A, Ongini E. The dopamine D1 receptor is involved in the regulation of REM sleep in the rat. Eur J Pharmacol 1991; 194: 189-194.
83. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52(9): 1908-1910.
84. Olanow CW, Schapira AH, Roth T. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole. Neurology 2000; 54(1): 274.
85. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord 2000; 15(2): 212-215.
86. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel JM, Mignot E. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res 1996; 733(1): 83-100.
87. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15(4): 658-663.
88. Reyner LA, Horne JA. Falling asleep whilst driving: are drivers aware of prior sleepiness? Int J Legal Med 1998; 111(3): 120-123.
89. Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 2001; 108(1): 71-77.
90. Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet 2000; 355(9212): 1332-1333.
91. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 2000; 355(9212): 1333-1334.
92. Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 2095-2101.
93. Arnulf I, Bejjani BP, Garma L, Bonnet AM, Houeto JL, Damier P, Derenne JP, Agid Y. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000; 55: 1732-1734.
94. Parkes JD. Variability in Parkinson's disease: clinical aspects, causes and treatment. Acta Neurol Scand 1983; 68(Suppl. 95): 27-35.
95. Comella CL, Stebbins GT, Bohmer J. Sleep benefit in Parkinson's disease. [Abstract] Neurology 1995; 45 (Suppl. 4): A286.
96. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38: 1553-1557.
97. Nutt JG, Carter JH, Woodward WRT et al. Diurnal patterns of motor function in Parkinson's disease. [Abstract] Neurology 1997; 48 (Suppl.2): A75.
98. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease. Imposing pharmacological law and order. Ann Neurol 1996; 39: 561-573.
99. Currie LJ, Bennett JP, Harrison MB, Trugman JM, Wooten GF. Clinical correlates of sleep benefit in Parkinson's disease. Neurology 1997; 48: 1115-1117.
100. Bliwise D, Rye D, Dihenia B et al. Periodic leg movements in elderly patients with parkinsonism. Sleep 1998; 21 (Suppl.): 196-200.
101. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6(Suppl. 4): 602-608.
102. Jouvet M, Delorme JF. Locus coeruleus et somneil paradoxal. C R Soc Biol 1965; 159: 895-899.
103. Garcia-Rill E. The pedunculopontine nucleus. Prog Neurobiol 1991; 36: 363-389.
104. Lai YY, Siegel JM. Muscle tone suppression and stepping produced by stimulation of midbrain and rostral pontine reticular formation. J Neurosci 1990; 10(8): 2727-2734.
105. Shouse MN, Siegel JM. Pontine regulation of REM sleep components in cats: integrity of the pedunculopontine tegmentum (PPT) is important for phasic events but unnecessary for atonia during REM sleep. Brain Res 1992; 571: 50-63.
106. Zarcone VPJ, Kryger MH, Roth T, Dement WC (eds). Principles and practice of sleep medicine. 3rd ed. Philadelphia: Saunders; 2000; Sleep hygiene. pp. 657-661.
107. Dorsey CM, Lukas SE, Teicher MH, Harper D, Winkelman JW, Cunningham SL, Satlin A. Effects of passive body heating on the sleep of older female insomniacs. J Geriatr Psychiatry Neurol 1996; 9(2): 83-90.
108. Dorsey CM, Teicher MH, Cohen-Zion M, Satlin A, Tartarini W, Harper D, Lukas SE. Core body temperature and sleep of older female insomniacs before and after passive body heating. Sleep 1999; 22(7): 891-898.
109. Ray Chaudhuri K, Bhattacharya K, Porter MC, Mills J, Clough C. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: a parallel study with controlled release levodopa. Eur J Neurol 1999; 6 (Suppl. 4): S11-S15.
110. Reuter I, Ellis CM, Chaudhuri K Ray. Use of subcutaneous apomorphine infusion for refractory nocturnal disabilities in Parkinson's disease including restless leg syndrome. Acta Neurol Scand 1999; 100: 163-167.
111. Ghatani T, Agapito C, Bhattacharya K, Clough C, Chaudhuri K Ray. Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal "off" periods causing sleep disruption in Parkinson's disease. Euro J Neurol 2001; 8(suppl. 1): 8-11.
112. Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinations in advanced Parkinson's disease. Lancet 1993; 341: 562-563.
113. Schenck CH, Hurwitz TD, Mahowald MW. REM sleep behavior disorder: an update on a series of 96 patients and a review of the world literature. J Sleep Res 1993; 2(4): 224-231.
114. Rye DB, Bliwise DL, Watts RL, Koller WC, (eds). Movement disorders: neurologic principles and practice. New York: McGraw-Hill; 1997; Movement Disorders Specific to Sleep and the Nocturnal Manifestations of Waking Movement Disorders. pp. 687-693.
115. Walters AS. Toward a better definition of the restless legs syndrome. Movement Disorders 1995; (5): 634-642.
116. Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol 2001; 248(7): 632-634.
117. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov Disord 2000; 15(6): 1269-1271.